Posts in tag

lysosomal


Under the terms of the agreement, Bioasis will get an upfront payment of US$3 million Bioasis Technologies Inc () () and Chiesi Global Rare Diseases have entered into a licensing agreement for Bioasis’ xB3 BBB platform technology to treat rare diseases with a focus on four undisclosed lysosomal storage disorders (LSDs). Under the terms of the agreement, …